tetano
Editor, Senior Moderator
J Clin Med
. 2020 Oct 22;9(11):E3386.
doi: 10.3390/jcm9113386.
Pediatric Inflammatory Multisystem Syndrome (PIMS) Did Occur in Poland during Months with Low COVID-19 Prevalence, Preliminary Results of a Nationwide Register
Magdalena Okarska-Napierała[SUP] 1 [/SUP], Kamila M Ludwikowska[SUP] 2 [/SUP], Leszek Szenborn[SUP] 2 [/SUP], Natalia Dudek[SUP] 1 [/SUP], Anna Mania[SUP] 3 [/SUP], Piotr Buda[SUP] 4 [/SUP], Janusz Książyk[SUP] 4 [/SUP], Katarzyna Mazur-Malewska[SUP] 3 [/SUP], Magdalena Figlerowicz[SUP] 3 [/SUP], Maciej Szczukocki[SUP] 5 [/SUP], Beata Kucińska[SUP] 6 [/SUP], Bożena Werner[SUP] 6 [/SUP], Lidia Stopyra[SUP] 7 [/SUP], Agnieszka Czech[SUP] 2 [/SUP], Elżbieta Berdej-Szczot[SUP] 8 [/SUP], Aneta Gawlik[SUP] 8 [/SUP], Paulina Opalińska[SUP] 9 [/SUP], Artur Mazur[SUP] 9 [/SUP], Danuta Januszkiewicz-Lewandowska[SUP] 10 [/SUP], Cezary Niszczota[SUP] 6 [/SUP], Teresa Jackowska[SUP] 11 [/SUP], Jacek Wysocki[SUP] 12 13 [/SUP], Mois CoR Study Group[SUP] 14 15 16 17 18 19 20 [/SUP], Ernest Kuchar[SUP] 1 [/SUP]
Affiliations
Abstract
Pediatric inflammatory multisystem syndrome (PIMS) is a new entity in children, likely associated with previous coronavirus disease 19 (COVID-19) infection. Most of the reports about PIMS come from countries particularly hit by the COVID-19 pandemic. Our aim was to investigate the nature of inflammatory syndromes in Poland (country with low COVID-19 prevalence) and to perceive the emergence of PIMS in our country. On 25 May 2020, we launched a nationwide survey of inflammatory syndromes in children for retrospective (since 4 March 2020) and prospective data collection. Up to 28 July, 39 reported children met the inclusion criteria. We stratified them according to age (<5 and ≥ 5 years old) and COVID-19 status. The majority of children had clinical and laboratory features of Kawasaki disease, probably non-associated with COVID-19. However, children ≥5 years of age had PIMS characteristics, and nine children had COVID-19 confirmation. This is, to our knowledge, the first report of the PIMS register from a country with a low COVID-19 prevalence, and it proves that PIMS may emerge in any area involved in the COVID-19 pandemic. In a context of limited COVID-19 testing availability, other risk factors of PIMS, e.g., older age, should be considered in the differential diagnosis of inflammatory syndromes in children.
Keywords: COVID-19; Kawasaki disease; MIS-C; PIMS; SARS-CoV-2; survey.
. 2020 Oct 22;9(11):E3386.
doi: 10.3390/jcm9113386.
Pediatric Inflammatory Multisystem Syndrome (PIMS) Did Occur in Poland during Months with Low COVID-19 Prevalence, Preliminary Results of a Nationwide Register
Magdalena Okarska-Napierała[SUP] 1 [/SUP], Kamila M Ludwikowska[SUP] 2 [/SUP], Leszek Szenborn[SUP] 2 [/SUP], Natalia Dudek[SUP] 1 [/SUP], Anna Mania[SUP] 3 [/SUP], Piotr Buda[SUP] 4 [/SUP], Janusz Książyk[SUP] 4 [/SUP], Katarzyna Mazur-Malewska[SUP] 3 [/SUP], Magdalena Figlerowicz[SUP] 3 [/SUP], Maciej Szczukocki[SUP] 5 [/SUP], Beata Kucińska[SUP] 6 [/SUP], Bożena Werner[SUP] 6 [/SUP], Lidia Stopyra[SUP] 7 [/SUP], Agnieszka Czech[SUP] 2 [/SUP], Elżbieta Berdej-Szczot[SUP] 8 [/SUP], Aneta Gawlik[SUP] 8 [/SUP], Paulina Opalińska[SUP] 9 [/SUP], Artur Mazur[SUP] 9 [/SUP], Danuta Januszkiewicz-Lewandowska[SUP] 10 [/SUP], Cezary Niszczota[SUP] 6 [/SUP], Teresa Jackowska[SUP] 11 [/SUP], Jacek Wysocki[SUP] 12 13 [/SUP], Mois CoR Study Group[SUP] 14 15 16 17 18 19 20 [/SUP], Ernest Kuchar[SUP] 1 [/SUP]
Affiliations
- PMID: 33105634
- DOI: 10.3390/jcm9113386
Abstract
Pediatric inflammatory multisystem syndrome (PIMS) is a new entity in children, likely associated with previous coronavirus disease 19 (COVID-19) infection. Most of the reports about PIMS come from countries particularly hit by the COVID-19 pandemic. Our aim was to investigate the nature of inflammatory syndromes in Poland (country with low COVID-19 prevalence) and to perceive the emergence of PIMS in our country. On 25 May 2020, we launched a nationwide survey of inflammatory syndromes in children for retrospective (since 4 March 2020) and prospective data collection. Up to 28 July, 39 reported children met the inclusion criteria. We stratified them according to age (<5 and ≥ 5 years old) and COVID-19 status. The majority of children had clinical and laboratory features of Kawasaki disease, probably non-associated with COVID-19. However, children ≥5 years of age had PIMS characteristics, and nine children had COVID-19 confirmation. This is, to our knowledge, the first report of the PIMS register from a country with a low COVID-19 prevalence, and it proves that PIMS may emerge in any area involved in the COVID-19 pandemic. In a context of limited COVID-19 testing availability, other risk factors of PIMS, e.g., older age, should be considered in the differential diagnosis of inflammatory syndromes in children.
Keywords: COVID-19; Kawasaki disease; MIS-C; PIMS; SARS-CoV-2; survey.